Enfuvirtide: Anti-HIV fusion inhibitor

Drugs of the Future

Volumn 27, Issue 5, 2002, Pages 450-457

  Cullell Young, M ^a   Leeson, P A ^a   Del Fresno, M ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 5 HELIX; ABACAVIR; AMD 8664; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 IMMUNOGLOBULIN G2; DEXTRIN; EFAVIRENZ; ENFUVIRTIDE; FP 21399; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; O (2 HYDROXYPROPYL) BETA CYCLODEXTRIN; RITONAVIR; SCH 350634; T 1249; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

EID: 0036320283     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.05.672277     Document Type: Review

References (44)

1. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
2. HIV fusion and its inhibition
3. Selection of gp41 mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non natural binding elements
4. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage
5. Capture of an early fusion active conformation of HIV-1 gp41
6. Inhibition of HIV-1 entry before gp41 folds into its fusion active conformation
7. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
8. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
9. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
10. Membrane-anchored peptide inhibits human immunodeficiency virus entry
11. T-20, a novel inhibitor of HIV-1 fusion blocks HIV-1 infection in vitro in human PBMC and macrophages and in vivo in the HuPBMC-SCID mouse model
12. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
13. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41
14. Sensitivity of HIV-1 to the fusion inhibitors T-20 and T-649 is modulated by coreceptor specificity and involves distinct regions of gp41
15. Sensitivity of HIV-1 to fusion inhibitors is modulated by coreceptor specificity and involves distinct regions of gp41
16. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
17. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
18. In vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779
19. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
20. Pentafuside (T20), a novel inhibitor of HIV-1 fusion and infection, is synergistic when used in combination with reverse transcriptase (RT) and protease inhibitors in vitro
21. T-20 and DAPD have synergistic in vitro anti-HIV interactions
22. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man
23. T-20, a novel inhibitor of HIV-1 fusion, blocks recovery of infectious HIV-1 and inhibits viral load in vivo in the HuPBMC-SCID mouse model
24. Pentafuside (T20), a novel inhibitor of HIV- 1 fusion: Pharmacokinetics and in vivo efficacy
25. Antiviral activity and pharmacokinetics of T-20, an amphipathic helical peptide derived from gp41
26. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man
27. Pentafuside (T-20): An amphipathic helical peptide-based membrane fusion inhibitor directed against HIV-1 gp41
28. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
29. Comparative PK of carbonate (CO3) and Tris buffer formulations of the peptide HIV fusion inhibitor T-20
30. Pharmacokinetics (PK) of selected doses of T20, a fusion inhibitor, in HIV-1-infected children
31. Pharmacokinetics (PK) of fusion inhibitor T-20 in HIV-1 infected patients
32. Safety, pharmacokinetics, and antiviral activity of T-20 as a single agent in heavily pre-treated patients
33. Chronic subcutaneous T-20 in HIV-1 infected children: Safety and anti-viral activity
34. A week-48 assessment of high strength T-20 formulations in multi-class experienced patients
35. A controlled phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir and efavirenz in non-nucleoside naive protease inhibitor experienced HIV-1 infected adults
36. A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naive patients infected with HIV-1
37. Patient satisfaction and activities of daily living (ADL) in HIV infected adults using T-20 given by subcutaneous injection (SC) over 48 weeks
38. Effects of peptide-induced humoral responses and preexisting antibodies in non-human primates and HIV-infected patients following chronic administration of T-20